06/06/2018
Admescope Ltd has acquired MetaSafe AB, a Swedish company specialised in the field of metabolic biotransformation research.
The acquisition creates a unique service offering, truly adding value to both Admescope’s and MetaSafe’s customers. MetaSafe’s top-notch knowledge in safety-related metabolism studies during drug development is a perfect addition to our comprehensive ADME-Tox portfolio and will further strengthen our drug metabolism services to clinical phase projects.
MetaSafe becomes an integrated part of Admescope; we will continue to operate the business in Södertälje, Sweden, with the existing team and invest in growing the site further. In addition to the new services the acquisition also gives us another location for high-quality laboratories.
We are very excited about the acquisition and are looking forward to serving our customers with the further strengthened service offering.
Please read the full press release here: https://www.admescope.com/whats-new/news/2018/06/press-release-admescope-has-acquired-metasafe-ab.html
